Trademark Overview
On Tuesday, April 8, 2025, a trademark application was filed for RAYFULI with the United States Patent and Trademark Office. The USPTO has given the RAYFULI trademark a serial number of 99126623. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Tuesday, April 8, 2025. This trademark is owned by Bristol-Myers Squibb Company. The RAYFULI trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes
